Engages in research and discovery of treatments for psychiatric disorders. Focuses on developing treatments for neurological disorders. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $55.2M in the vault; even if every debt were paid off, $55.2M would remain.
Over the last 12 months, company executives reported 37 buys and 3 sells. Management buying with its own money is usually read as a good sign.
A loss of $20.4M against $0 in annual sales.
The stock sits at $0.53. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, KTTA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: KTTA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (10/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.